{
  "nctId": "NCT04320940",
  "briefTitle": "Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures",
  "officialTitle": "A Randomized, Double-Blind, Controlled Study to Assess the Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures",
  "protocolDocument": {
    "nctId": "NCT04320940",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-12-07",
    "uploadDate": "2023-08-22T16:16",
    "size": 665575,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04320940/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 4,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-03-12",
    "completionDate": "2023-02-01",
    "primaryCompletionDate": "2023-02-01",
    "firstSubmitDate": "2020-03-23",
    "firstPostDate": "2020-03-25"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)\n* Parental informed consent (in-person or remote consent)\n* Undergoing continuous video electroencephalogram (cvEEG) monitoring\n* Has evidence of electrographic seizure burden of at least 30 seconds/h\n\nExclusion Criteria:\n\n* Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation \\> 24 hours before enrollment)\n* Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization\n* Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder\n* Death appears to be imminent as assessed by the NICU attending physician\n* Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "34 Weeks",
    "maximumAge": "44 Weeks",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.",
        "description": "Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.",
        "timeFrame": "24 hours"
      }
    ],
    "secondary": [
      {
        "measure": "Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.",
        "description": "Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.",
        "description": "Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.",
        "timeFrame": "24 hours"
      },
      {
        "measure": "Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.",
        "description": "Number of subject required monitoring of seizure burden over 48 hours following initial administration of the phenobarbital injection.",
        "timeFrame": "48 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:49.966Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}